Publicação

Macular Cystoid Edema Induced by Nab-Paclitaxel

Ver documento

Detalhes bibliográficos
Resumo:A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis.
Autores principais:Alves Pereira, Sara
Outros Autores:Vale, Carolina; Moreira, Jorge; Sampaio, Filipa
Assunto:Albumins/adverse effects Albumin-Bound Paclitaxel/adverse effects Macular Edema/chemically induced Paclitaxel/adverse effects Pancreatic Neoplasms/drug therapy Albuminas/efeitos adversos Edema Macular/induzido quimicamente Neoplasias Pancreáticas/tratamento farmacológico Paclitaxel/efeitos adversos Paclitaxel Ligado a Albumina/efeitos adversos
Ano:2022
País:Portugal
Tipo de documento:artigo
Tipo de acesso:unknown
Instituição associada:Ordem dos Médicos
Idioma:inglês
Origem:Acta Médica Portuguesa
Descrição
Resumo:A 61-year old male was referred to the Ophthalmology department because of decreased bilateral visual acuity. The patient had metastatic pancreatic adenocarcinoma and was being treated with gemcitabine+nab-paclitaxel. On examination, the patient presented best corrected visual acuities of 4/20 and 2/20 in the right and left eye, respectively. The optical coherence tomography revealed bilateral severe macular edema. Macular edema was considered secondary to nab-paclitaxel and the drug was discontinued. Three months after drug discontinuation, the patient presented best corrected visual acuities of 20/20 and 16/20 in the right and left eye, respectively, and normal fundoscopy. Macular edema is a very rare side effect of taxanes, and the etiopathology is still unknown. Edema is usually reversible upon discontinuation of the offending agent. Clinicians should be aware of this adverse effect of taxanes, and a high index of clinical suspicion is essential for diagnosis.